- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05369208
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
January 24, 2024 updated by: Sobi, Inc.
An Open-label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic Immune Thrombocytopenia
Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This Phase 3, multicenter, open label study will evaluate the efficacy, safety, and population pharmacokinetics (PK) of avatrombopag in Japanese adults with chronic ITP.
At least 19 subjects will be enrolled.
The study will consist of 3 phases: Pre-enrollment, Primary Investigation, and Extension Phase until market authorization in Japan.
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sobi Clinical
- Phone Number: 781-786-7370
- Email: NAClinical@Sobi.com
Study Locations
-
-
Aichi
-
Toyohashi, Aichi, Japan, 441-8570
- Sobi Site 105
-
-
Ehime
-
Toon City, Ehime, Japan, 791-0295
- Sobi Site 110
-
-
Fukuoka
-
Iizuka-shi, Fukuoka, Japan, 820-8505
- Sobi Site 118
-
Kitakyushu City, Fukuoka, Japan, 802-8555
- Sobi Site 116
-
Kurume City, Fukuoka, Japan, 830-8543
- Sobi Site 117
-
-
Gifu
-
Gifu City, Gifu, Japan, 500-8513
- Sobi Site 114
-
-
Hiroshima
-
Fukuyama-shi, Hiroshima, Japan, 720-2121
- Sobi Site 115
-
Hiroshima City, Hiroshima, Japan, 730-0052
- Sobi Site 109
-
-
Hyogo
-
Kobe, Hyogo, Japan, 650-0047
- Sobi Site 108
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8650
- Sobi Site 113
-
-
Iwata
-
Shiwa-gun, Iwata, Japan, 028-3695
- Sobi Site 101
-
-
Kanagawa
-
Fujisawa City, Kanagawa, Japan, 251-8550
- Sobi Site 111
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan, 862-8655
- Sobi Site 119
-
-
Osaka
-
Hirakata City, Osaka, Japan, 573-1191
- Sobi Site 107
-
Suita, Osaka, Japan, 565-0871
- Sobi Site 106
-
-
Tokyo
-
Hachiōji-shi, Tokyo, Japan, 192-0032
- Sobi Site 104
-
-
Toyko
-
Bunkyō-Ku, Toyko, Japan, 113-8603
- Sobi Site 103
-
-
Yamanashi
-
Chuo-shi, Yamanashi, Japan, 409-3898
- Sobi Site 102
-
Kōfu, Yamanashi, Japan, 400-8506
- Sobi Site 112
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject has a confirmed diagnosis of chronic immune thrombocytopenia (ITP) (≥12 months duration) and has had an insufficient response to a previous ITP treatment, in the opinion of the Investigator.
- Subject has an average of 2 platelet counts <30×10^9/L (no single count can be >35×10^9/L). The 2 samples must be obtained ≥48 hours and ≤2 weeks apart.
Exclusion Criteria:
- Subjects with known secondary immune thrombocytopenia (e.g., with known Helicobacter pylori-induced ITP, subjects infected with known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) or subjects with known systemic lupus erythematosus).
- Subjects with known inherited thrombocytopenia (e.g., Myosin Heavy Chain 9 (MYH-9) disorders) or hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency).
- History of myelodysplastic syndrome (MDS).
- History of arterial or venous thrombosis.
- Subjects with a history of significant cardiovascular disease (e.g., congestive heart failure (CHF) New York Heart Association Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], angina, coronary artery stent placement, angioplasty, coronary artery bypass grafting).
- Subjects with a history of cirrhosis, portal hypertension, or chronic active hepatitis.
- Subjects with concurrent malignant disease or receiving cytotoxic chemotherapy for a reason other than ITP treatment.
- Use of immunoglobulins (IVIg and anti-D) or corticosteroid rescue therapy within 1 week of Day 1/Baseline.
- Splenectomy or use of rituximab within 12 weeks of Day 1/Baseline.
- Use of romiplostim or eltrombopag within 1 week of Day 1/Baseline.
- Use of chronic corticosteroid treatment or azathioprine within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 4 weeks.
- Use of mycophenolate mofetil, cyclosporin A, or danazol within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 12 weeks.
- Use of cyclophosphamide or vinca alkaloid regimens within 4 weeks of Baseline Visit.
- Currently receiving moderate or strong dual inhibitors/inducers of CYP2C9 and CYP3A4.
- Serum creatinine ≥1.5× the upper limit of normal (ULN).
- Serum bilirubin ≥2×ULN.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3×ULN.
- Females who are pregnant (positive beta-human chorionic gonadotropin (β-hCG) test) or breastfeeding.
- Received treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) before Day 1/Baseline.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Avatrombopag
Avatrombopag 20 mg oral tablet
|
Avatrombopag 20 mg given once daily (initial dose).
Dose adjustments will be determined by the physician and in accordance with the overseas Doptelet prescribing information.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Number of Weeks of Platelet Response
Time Frame: 26 weeks of active treatment
|
Cumulative number of weeks in which the platelet count is ≥50×10^9/L during 26 weeks of treatment in the absence of rescue therapy.
|
26 weeks of active treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate at Day 8
Time Frame: Day 8
|
Proportion of subjects with a platelet response ≥50×10^9/L at Day 8 in the absence of rescue therapy
|
Day 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2022
Primary Completion (Actual)
January 17, 2024
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
April 21, 2022
First Submitted That Met QC Criteria
May 5, 2022
First Posted (Actual)
May 11, 2022
Study Record Updates
Last Update Posted (Estimated)
January 25, 2024
Last Update Submitted That Met QC Criteria
January 24, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
Other Study ID Numbers
- AVA-ITP-307
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenia
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
-
University Children's Hospital BaselNovartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaboratorsActive, not recruiting
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedAdult Patients | Immune Primary Thrombocytopenia | Splenectomy | TPO-mimeticsItaly
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
Changzhou No.2 People's HospitalRui Therapeutics Co., LtdNot yet recruitingThrombocytopenia Alloimmune
-
Nahda UniversityRecruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
Clinical Trials on Avatrombopag Oral Tablet
-
Sobi, Inc.CompletedImmune ThrombocytopeniaUnited States
-
Sobi, Inc.CompletedChemotherapy-induced ThrombocytopeniaUnited States, China, Hungary, Poland, Russian Federation, Serbia, Ukraine
-
Sobi, Inc.Withdrawn
-
Institute of Hematology & Blood Diseases Hospital...Fosun Pharmaceutical Distribution Jiangsu co., LimitedNot yet recruiting
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Tianjin Medical University Second Hospital; The Second... and other collaboratorsRecruitingImmune Thrombocytopenia | TreatmentChina
-
Peking Union Medical College HospitalRecruitingThrombocytopenia | AvatrombopagChina
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada